Sign in
4

Changes in Ownership

Rapport Therapeutics, Inc. Filed Acc 0001193125-26-167091

Chief Development Officer sold 20,225 shares at $39.99 ($808,844)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Yeleswaram Krishnaswamy Chief Development Officer 2026-04-17 Sale 10b5-1 −20,225 $39.99 $808,844 246,426 D
Open-market sales · 20,225 sh · avg $39.99 · $808,844
Loading xslF345X06/ownership.xml…